Study identified the novel molecular relationship between FOXP1 and genes essential to immune response
“FOXP1 suppresses immune response signatures and MHC class II expression in activate B-cell like diffuse large B-cell lymphoma” is a new study that was recently published in the Leukemia journal. The study identified the transcription factor FOXP1 as the main regulator in cancer cells’ ability to evade immune responses in patients with diffuse large B-cell lymphomas (DLBCL).
DLBCL is an aggressive B-cell non-Hodgkin lymphoma (NHL) and is the most common type of NHL accounting for 30% to 40% of all cases. The average age of diagnosis for DLBCL is the mid-sixties, however, this cancer can also affect children. Learn more about DLBCL
Lymphoma News Today - Molecular Key Found in Diffuse Large B-cell Lymphoma Development